Drug Trial Radar · NCT01431287
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Jul 16, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,539
Actual
Start
Sep 2011
Primary completion
Nov 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 9, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components (tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with COPD.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterolDrug
fixed dose combination
tiotropium + olodaterolDrug
fixed dose combination
tiotropiumDrug
low dose or high dose
tiotropiumDrug
low dose or high dose
olodaterolDrug
one dose only
RespimatDevice
Respimat inhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169Time frame: 1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169
- Trough FEV1 Response on Day 170Time frame: 1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170
- Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).Time frame: Day 169
Locations
240 sites in 24 countries. Site status is shown where the registry gives one.
1237.6.01106 Boehringer Ingelheim Investigational Site
Greer, California
1237.6.01120 Boehringer Ingelheim Investigational Site
Fort Collins, Colorado
1237.6.01131 Boehringer Ingelheim Investigational Site
Danbury, Connecticut
1237.6.01117 Boehringer Ingelheim Investigational Site
Waterbury, Connecticut
1237.6.01118 Boehringer Ingelheim Investigational Site
DeLand, Florida
1237.6.01126 Boehringer Ingelheim Investigational Site
Tampa, Florida
1237.6.01109 Boehringer Ingelheim Investigational Site
Winter Park, Florida
1237.6.01134 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
1237.6.01107 Boehringer Ingelheim Investigational Site
Couer d'Alene, Idaho
1237.6.01110 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana
1237.6.01128 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
1237.6.01130 Boehringer Ingelheim Investigational Site
North Dartmouth, Massachusetts
1237.6.01104 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota
1237.6.01116 Boehringer Ingelheim Investigational Site
Plymouth, Minnesota
1237.6.01121 Boehringer Ingelheim Investigational Site
St Louis, Missouri
1237.6.01123 Boehringer Ingelheim Investigational Site
St Louis, Missouri
1237.6.01129 Boehringer Ingelheim Investigational Site
Henderson, Nevada
1237.6.01136 Boehringer Ingelheim Investigational Site
Marlton, New Jersey
1237.6.01108 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico
1237.6.01127 Boehringer Ingelheim Investigational Site
Bayside, New York
1237.6.01139 Boehringer Ingelheim Investigational Site
Great Neck, New York
1237.6.01135 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina
1237.6.01114 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
1237.6.01102 Boehringer Ingelheim Investigational Site
Columbus, Ohio
1237.6.01115 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma
1237.6.01101 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania
1237.6.01113 Boehringer Ingelheim Investigational Site
East Providence, Rhode Island
1237.6.01122 Boehringer Ingelheim Investigational Site
Charleston, South Carolina
1237.6.01132 Boehringer Ingelheim Investigational Site
Greenville, South Carolina
1237.6.01137 Boehringer Ingelheim Investigational Site
Greenville, South Carolina
1237.6.01111 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina
1237.6.01105 Boehringer Ingelheim Investigational Site
Union, South Carolina
1237.6.01138 Boehringer Ingelheim Investigational Site
Killeen, Texas
1237.6.01124 Boehringer Ingelheim Investigational Site
McKinney, Texas
1237.6.01112 Boehringer Ingelheim Investigational Site
Richmond, Virginia
1237.6.01133 Boehringer Ingelheim Investigational Site
Richmond, Virginia
1237.6.01125 Boehringer Ingelheim Investigational Site
Spokane, Washington
1237.6.01103 Boehringer Ingelheim Investigational Site
Tacoma, Washington
1237.6.43006 Boehringer Ingelheim Investigational Site
Feldbach, Austria
1237.6.43005 Boehringer Ingelheim Investigational Site
Gänserndorf, Austria
Showing 40 of 240 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.